<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171020036896N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-06-05</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Clinical success and pain of two  anesthetics methods of Inferior Alveolar Nerve Block  and crestal anesthesia and two anesthetics materials of lidocaine and articaine in the crestal anesthesia for pulpotomy treatment of  primary molars</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of two  anesthetics methods of Inferior Alveolar Nerve Block  and crestal anesthesia and two anesthetics materials of lidocaine and articaine in the crestal anesthesia for pulpotomy treatment of  primary molars</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54287</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the simple randomization method (flip the coin) will be used. In such a way that one of the study groups will be considered as heads and the other group will be considered as tails. Then the same number of coins will be thrown based on the sample size. Finally, to prevent  disclosure of random sequencing, the  allocation concealment will be used, Blinding description: The patient is not aware of local anesthetic agent and technique at the time of treatment. Statistics consultant is not aware of local anesthetic agent and technique at the time of treatment too.</study_design>
      <phase>2</phase>
      <hc_freetext>Condition 1: The comparison of  effect of inferior alveolar nerve block  and crestal local anesthesiain  in pulpotomy of primary teeth. Condition 2: The effect of crestal local anesthesia using lidocaine in pulpotomy of primary teeth. Condition 3: The effect of crestal local anesthesia using articaine in pulpotomy of primary teeth.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: In this group, in the first session,  pulpotomy of a mandibular primary molar will be performed by injecting inferior alveolar nerve block using lidocaine  2%  with epinephrine 1: 100,000 (produced by Iran Pharmaceutical Company) and in the second session, pulpotomy of a primary molar will be performed on the other side of the mandible by crestal local injection using lidocaine 2% with epinephrine 1: 100000 (produced by Iran Pharmaceutical Company). Before and after the local anesthetic injection, changes in the child's pulse is measured using a pulse oximeter in both sessions. After an appropriate time (10 minutes) to determine the time of onset of anesthesia, IANB anesthesia is tested with a catheter after the child's lip feels numb, and CA anesthesia is tested immediately after injection into the second papilla. Then the caries removal process and preparation of the access cavity begin and the child's reaction is measured at the moment of pulp exposure. Before the treatment, the assistant will explain the Visual Analogue Scale (VAS) to the child and how to display the amount of discomfort on it, and immediately while preparing the access cavity in dentin or in case of need for pulp treatment at the time of pulp exposure. The child is asked to rate one of the smileys from zero (painless) to 10 (unbearable pain) based on the intensity of the pain he feels. The result is then recorded on the child form. Intervention 2: Intervention group 2: In this group, in the first session,  pulpotomy of a mandibular primary molar will be performed by crestal local injection  using lidocaine  2%  with epinephrine 1: 100,000 (produced by Iran Pharmaceutical Company) and in the second session, pulpotomy of a primary molar will be performed on the other side of the mandible by crestal local injection using articaine 4% with epinephrine 1: 100000 (produced by Iran Pharmaceutical Company). Before and after the local anesthetic injection, changes in the child's pulse is measured using a pulse oximeter in both sessions. To determine the time of onset of anesthesia, CA anesthesia is tested immediately after injection into the second papilla. Then the caries removal process and preparation of the access cavity begin and the child's reaction is measured at the moment of pulp exposure. Before the treatment, the assistant will explain the Visual Analogue Scale (VAS) to the child and how to display the amount of discomfort on it, and immediately while preparing the access cavity in dentin or in case of need for pulp treatment at the time of pulp exposure. The child is asked to rate one of the smileys from zero (painless) to 10 (unbearable pain) based on the intensity of the pain he feels. The result is then recorded on the child form.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Because what you have read is in addition to analyzing additional scientific application</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parisa Jafari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shafa Ave</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618759689</zip>
        <telephone>+98 34 8074 3211</telephone>
        <email>Parisajafaridnt@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parisa Jafari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shafa Ave</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618759689</zip>
        <telephone>+98 34 8074 3211</telephone>
        <email>Parisajafaridnt@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children who need a bilateral pulpotomy of deciduous molars (D or E) in the mandible based on clinical signs and radiography and at the diagnosis of a pediatric dentist.
Age category 4 to 8 years
Parents' consent to participate in the study</inclusion_criteria>
      <agemin>4 years</agemin>
      <agemax>8 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having a history of systemic disease
Having severe fear and anxiety
Using painkillers to control toothache
Having acute dental infections
Having deciduous molars that have more than two thirds of their roots analyzed</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: In this group, in the first session,  pulpotomy of a mandibular primary molar will be performed by injecting inferior alveolar nerve block using lidocaine  2%  with epinephrine 1: 100,000 (produced by Iran Pharmaceutical Company) and in the second session, pulpotomy of a primary molar will be performed on the other side of the mandible by crestal local injection using lidocaine 2% with epinephrine 1: 100000 (produced by Iran Pharmaceutical Company). Before and after the local anesthetic injection, changes in the child's pulse is measured using a pulse oximeter in both sessions. After an appropriate time (10 minutes) to determine the time of onset of anesthesia, IANB anesthesia is tested with a catheter after the child's lip feels numb, and CA anesthesia is tested immediately after injection into the second papilla. Then the caries removal process and preparation of the access cavity begin and the child's reaction is measured at the moment of pulp exposure. Before the treatment, the assistant will explain the Visual Analogue Scale (VAS) to the child and how to display the amount of discomfort on it, and immediately while preparing the access cavity in dentin or in case of need for pulp treatment at the time of pulp exposure. The child is asked to rate one of the smileys from zero (painless) to 10 (unbearable pain) based on the intensity of the pain he feels. The result is then recorded on the child form.</i_keyword>
      <i_keyword>Intervention group 2: In this group, in the first session,  pulpotomy of a mandibular primary molar will be performed by crestal local injection  using lidocaine  2%  with epinephrine 1: 100,000 (produced by Iran Pharmaceutical Company) and in the second session, pulpotomy of a primary molar will be performed on the other side of the mandible by crestal local injection using articaine 4% with epinephrine 1: 100000 (produced by Iran Pharmaceutical Company). Before and after the local anesthetic injection, changes in the child's pulse is measured using a pulse oximeter in both sessions. To determine the time of onset of anesthesia, CA anesthesia is tested immediately after injection into the second papilla. Then the caries removal process and preparation of the access cavity begin and the child's reaction is measured at the moment of pulp exposure. Before the treatment, the assistant will explain the Visual Analogue Scale (VAS) to the child and how to display the amount of discomfort on it, and immediately while preparing the access cavity in dentin or in case of need for pulp treatment at the time of pulp exposure. The child is asked to rate one of the smileys from zero (painless) to 10 (unbearable pain) based on the intensity of the pain he feels. The result is then recorded on the child form.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Immediately after the crestal injection, the child's pain is measured  by the VAS (Visual Analogue Scale) during the opening of the dental pulp. Method of measurement: The child's pain is measured by the VAS (Visual Analogue Scale).</prim_outcome>
      <prim_outcome>Changes in the heart rate to determine the amount of pain experienced by the child during the crestal injection. Timepoint: Changes in a child's heart rate are made by using a pulse oximeter  5 seconds before and immediately after the local anesthetic injection. Method of measurement: Changes in a child's heart rate are made by using a pulse oximeter  5 seconds before and immediately after the local anesthetic injection.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-01</approval_date>
        <contact_name>Ethics Committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>shafa street kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
